These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 24683016)
1. [Prevalence of metabolic complications after 10 years of antiretroviral treatment in Senegal]. Diouf A; Cournil A; Bull Soc Pathol Exot; 2014 Oct; 107(4):234-7. PubMed ID: 24683016 [TBL] [Abstract][Full Text] [Related]
2. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients. Feleke Y; Fekade D; Mezegebu Y Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405 [TBL] [Abstract][Full Text] [Related]
3. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study. Mercier S; Gueye NF; Cournil A; Fontbonne A; Copin N; Ndiaye I; Dupuy AM; Cames C; Sow PS; Ndoye I; Delaporte E; Simondon KB J Acquir Immune Defic Syndr; 2009 Jun; 51(2):224-30. PubMed ID: 19339897 [TBL] [Abstract][Full Text] [Related]
4. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection. Barbaro G Curr HIV Res; 2006 Jan; 4(1):79-85. PubMed ID: 16454713 [TBL] [Abstract][Full Text] [Related]
5. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. van Griensven J; De Naeyer L; Mushi T; Ubarijoro S; Gashumba D; Gazille C; Zachariah R Trans R Soc Trop Med Hyg; 2007 Aug; 101(8):793-8. PubMed ID: 17467756 [TBL] [Abstract][Full Text] [Related]
6. Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study. Cames C; Pascal L; Ba A; Mbodj H; Ouattara B; Diallo NF; Msellati P; Mbaye N; Sy Signate H; Blanche S; Diack A; BMC Infect Dis; 2018 Aug; 18(1):374. PubMed ID: 30081838 [TBL] [Abstract][Full Text] [Related]
7. The metabolic syndrome, an epidemic among HIV-infected patients on HAART. Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676 [TBL] [Abstract][Full Text] [Related]
8. HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities. Moyle G; Carr A HIV Clin Trials; 2002; 3(1):89-98. PubMed ID: 11894812 [No Abstract] [Full Text] [Related]
9. Prevalence of diabetes mellitus, hyperinsulinaemia and metabolic syndrome among 755 adult patients with HIV-1 infection. Calza L; Masetti G; Piergentili B; Trapani F; Cascavilla A; Manfredi R; Colangeli V; Viale P Int J STD AIDS; 2011 Jan; 22(1):43-5. PubMed ID: 21364066 [TBL] [Abstract][Full Text] [Related]
10. Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in northern India. Bhutia E; Hemal A; Yadav TP; Ramesh KL Afr Health Sci; 2014 Jun; 14(2):408-13. PubMed ID: 25320591 [TBL] [Abstract][Full Text] [Related]
11. [Metabolic disorders and lipodystrophy. Adverse effects of antiretroviral therapy]. Goebel FD; Westner I MMW Fortschr Med; 2001 Apr; 143 Suppl 1():40-4. PubMed ID: 11373778 [TBL] [Abstract][Full Text] [Related]
12. What should we know about metabolic syndrome and lipodystrophy in AIDS? Signorini DJ; Monteiro MC; Andrade Mde F; Signorini DH; Eyer-Silva Wde A Rev Assoc Med Bras (1992); 2012; 58(1):70-5. PubMed ID: 22392319 [TBL] [Abstract][Full Text] [Related]
13. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients. Tin EE; Bowonwatanuwong C; Desakorn V; Wilairatana P; Krudsood S; Pitisuttithum P Southeast Asian J Trop Med Public Health; 2005 Mar; 36(2):362-9. PubMed ID: 15916042 [TBL] [Abstract][Full Text] [Related]
14. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents. Fantoni M; Del Borgo C; Autore C; Barbaro G Ital Heart J; 2002 May; 3(5):294-9. PubMed ID: 12066561 [TBL] [Abstract][Full Text] [Related]